Results 171 to 180 of about 137,339 (254)

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network (EMN) Italy

British Journal of Haematology, EarlyView.
Summary The extensive use of lenalidomide (Len) in the first‐line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len‐R) at first relapse. However, the outcome of Len‐R patients treated at first relapse after autologous haematopoietic stem cell transplantation (AHSCT)
Gregorio Barilà, Angela Grassi, Valeria Ruocco, Carmine Liberatore, Edoardo Olivari, Martina Tinelli, Francesca Fazio, Sonia Morè, Emanuele Favero, Claudio Salvatore Cartia, Nicola Sgherza, Concetta Conticello, Roberto Mina, Martina Gherardini, Giuseppe Mele, Massimo Gentile, Anna Furlan, Massimiliano Arangio Febbo, Maria Livia Del Giudice, Ombretta Annibali, Bernardo Rossini, Edoardo Scomazzon, Marco Talarico, Enrica Antonia Martino, Claudio De Magistris, Francesca Fioritoni, Anna Maria Cafro, Laura Paris, Sara Pezzatti, Roberta Della Pepa, Paola Boggione, Giuseppe Pietrantuono, Valeria Tomarchio, Francesco Vassallo, Maria Luisa Pioltelli, Francesco Pisani, Antonia Cagnetta, Lorenzo De Paoli, Gabriele Buda, Elisabetta Antonioli, Monica Galli, Alberto Tosetto, Pellegrino Musto, Elena Zamagni, Francesca Patriarca, Silvia Mangiacavalli, Renato Zambello, Massimo Offidani, Maria Teresa Petrucci   +48 more
wiley   +1 more source

Ribosomal architecture and rRNA modification landscape in the tick-borne parasite Babesia divergens. [PDF]

Nat Commun
Gutierrez-Vargas C, Izhaki-Tavor LS, Calvopina-Chavez DG, Keroack CD, Copello P, Duraisingh MT, Léger-Abraham M.   +6 more
europepmc   +1 more source

Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

British Journal of Haematology, EarlyView.
Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler‐Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer‐Ausch, Sigrid Machherndl‐Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria‐Theresa Krauth   +23 more
wiley   +1 more source

Characteristics, treatment regimens, and outcomes of patients with true extramedullary multiple myeloma: a real-world monocentric analysis. [PDF]

Ann Hematol
Harzer M, Gross-Fengels N, Melzer F, Molwitz I, Kosch R, Al-Bazaz M, Artzenroth J, Cords L, Bartke L, Kamili A, Alsdorf W, Bokemeyer C, Weisel K, Leypoldt LB, Schaefers C.   +14 more
europepmc   +1 more source

Chemoproteomic discovery of a brain‐penetrant, covalent NLRP3 inhibitor that binds a novel allosteric pocket

British Journal of Pharmacology, EarlyView.
NLRP3 is a promising inflammatory target, but existing inhibitors lack diversity and brain penetrance, and none are approved. Using chemoproteomics, we discovered a novel series that binds to Cys463 in a previously uncharacterized pocket. Compounds showed nanomolar potency, brain exposure, and in vivo suppression of IL‐1β, supporting neuroinflammatory ...
Donald C. Rogness, Evelyn P. Sievert, Vincent F. Vartabedian, Steffen M. Bernard, Erick Aitchison, William Tao, Mikaela Lindvall, Jing Qian, Christie L. Eissler, Brian E. Nordin, Benjamin D. Horning, Cian Kingston, Kelsey N. Lamb, Joshua C. Bell, Bingwen Lu, Jonathan Pollock, Jun Shi, Roli Khattri, David S. Weinstein, Matthew P. Patricelli, Brian N. Cook, Gabriel M. Simon   +21 more
wiley   +1 more source

Dual-targeting bispecific antibodies against extramedullary myeloma: A hypothesis-driven commentary. [PDF]

Transl Oncol
Zhou S, Ke Q.
europepmc   +1 more source

Perioperative Durvalumab for Resectable NSCLC: Updated Outcomes for Japanese Patients in AEGEAN

Cancer Science, EarlyView.
In prespecified exploratory analyses of Japanese patients with resectable NSCLC enrolled in the AEGEAN trial, perioperative durvalumab plus neoadjuvant chemotherapy demonstrated clinically meaningful improvements in the primary endpoints of EFS and pCR versus neoadjuvant chemotherapy alone.
Tetsuya Mitsudomi, John V. Heymach, Yoshitsugu Horio, Fumihiro Tanaka, Hiroshi Tanaka, Shoichi Kuyama, Morihito Okada, Shinichi Toyooka, Yasutaka Watanabe, Martin Reck, David Harpole, Janis M. Taube, Yuka Olivo, Huiling Xiong, Tamer M. Fouad, Allen Chen, Hiroaki Akamatsu   +16 more
wiley   +1 more source

EMD-HVG: a normalization-independent method for highly variable gene selection based on Earth mover's distance. [PDF]

BMC Bioinformatics
Peng C, Li G, Wu J, Tan F, Guo X.
europepmc   +1 more source

Mitochondria‐Directed Redox Phospholipid Polymers for Cancer Therapy

Cancer Science, EarlyView.
A mitochondria‐directed redox polymer containing an antioxidant‐oxidizing ferrocene unit and a triphenylphosphonium unit is prepared by a simple copolymerization strategy for cancer treatment. Incorporation of an appropriate amount of the directed unit enhances anticancer activity, elevates intracellular ROS levels, induces apoptosis, and suppresses in 
Yuma Kato, Yuki Ogawa, Akira Ito, Masahiro Kaneko   +3 more
wiley   +1 more source

Interactive segmentation of membrane and membrane-mimic densities in cryo-EM maps. [PDF]

Acta Crystallogr D Struct Biol
Bharadwaj A, Veerbeek L, Jakobi A.
europepmc   +1 more source